Literature DB >> 20883543

An early regional experience with expansion of Milan Criteria for liver transplant recipients.

J J Guiteau1, R T Cotton, W K Washburn, A Harper, C A O'Mahony, A Sebastian, S Cheng, G Klintmalm, M Ghobrial, G Halff, L Mieles, J Goss.   

Abstract

The Milan Criteria (MC) showed that orthotopic liver transplantation (OLT) was an effective treatment for patients with nonresectable, nonmetastatic HCC. There is growing evidence that expanding the MC does not adversely affect patient or allograft survival following OLT. The adult OLT programs in UNOS Region 4 reached an agreement allowing lesions outside MC (one lesion <6 cm, ≤3 lesions, none >5 cm and total diameter <9 cm-[R4 T3]) to receive the same exception points as MC lesions. Kaplan-Meier curves and log-rank tests were used to compare survival data. Chi-squared and Mann-Whitney U tests were used to compare patient data. A p-value of <0.05 was considered significant. All statistical analyses were performed on SPSS 15 (SPSS, Chicago, IL). Four hundred and forty-five patients were transplanted for HCC (363-MC and 82-R4 T3). Patient demographics were found to be similar between the two groups. Three year patient, allograft and recurrence free survival between MC and R4 T3 were found to be 72.9% and 77.1%, 71% and 70.2% and 90.5% and 86.9%, respectively (all p > 0.05). We report the first regionalized multicenter, prospective study showing benefit of OLT in patients exceeding MC based on preoperative imaging.
© 2010 The Authors Journal compilation © 2010 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2010        PMID: 20883543     DOI: 10.1111/j.1600-6143.2010.03222.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

1.  Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.

Authors:  Seung Duk Lee; Bora Lee; Seong Hoon Kim; Jungnam Joo; Seok-Ki Kim; Young-Kyu Kim; Sang-Jae Park
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.

Authors:  Nicole E Rich; Neehar D Parikh; Amit G Singal
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

3.  Standardizing MELD Exceptions: Current Challenges and Future Directions.

Authors:  David S Goldberg; Kim M Olthoff
Journal:  Curr Transplant Rep       Date:  2014-12-01

Review 4.  New advances in hepatocellular carcinoma.

Authors:  Sonia Pascual; Iván Herrera; Javier Irurzun
Journal:  World J Hepatol       Date:  2016-03-28

Review 5.  Living donor liver transplantation in the USA.

Authors:  Peter T W Kim; Giuliano Testa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

6.  Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation.

Authors:  Jie Hu; Zheng Wang; Jia Fan; Zhi Dai; Yi-Feng He; Shuang-Jian Qiu; Xiao-Wu Huang; Jian Sun; Yong-Sheng Xiao; Kang Song; Ying-Hong Shi; Qi-Man Sun; Xin-Rong Yang; Guo-Ming Shi; Lei Yu; Guo-Huan Yang; Zhen-Bin Ding; Qiang Gao; Zhao-You Tang; Jian Zhou
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

Review 7.  Current Treatment Approaches to HCC with a Special Consideration to Transplantation.

Authors:  N Bhardwaj; M T P R Perera; M A Silva
Journal:  J Transplant       Date:  2016-06-20

8.  The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.

Authors:  Da-Li Zhang; Dan-Ni Feng; Xi He; Xiao-Feng Zhang; Li-Xin Li; Zhi-Jie Li; Xiao-Feng Niu; Yun-Long Zhuang; Zhen-Wen Liu; Xu-Dong Gao; Hong-Bo Wang
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.